MED
The topline keeps sliding
Medifast just dropped its second-quarter 2026 results, and the vibe is still very much “business model in a blender.” Revenue came in at $76.4 million, while the company posted a $3.1 million net loss, or $0.28 per diluted share. Not exactly the kind of print that gets investors popping champagne, unless the champagne is being used to numb the pain.
The coach count is the canary
One of the more telling numbers here is the 11,700 independent active earning coaches. That figure matters because Medifast’s system leans heavily on its coach-driven model to bring in and keep customers. When that base shrinks or stalls, the whole machine can start to feel like a treadmill set to “why is this getting harder?”
Cash is the silver lining
The one thing that looks sturdier is the balance sheet. Medifast ended the quarter with $169.8 million in cash, cash equivalents, and investment securities. That won’t magically solve the growth problem, but it does give management time to keep tinkering with the playbook instead of running for the emergency exit.
Big picture
For investors, this is still a story about whether Medifast can stabilize demand and rebuild momentum in a business that’s clearly not firing on all cylinders. The cash cushion helps, but the real question is whether the next quarter looks like a turnaround — or just another status update on the way down.